Matched therapy based on IHC consisted of trastuzumab for ERBB2 amplification, pembrolizumab for MMR deficiency, pan-ERBB inhibitor for EGFR+, and PI3Kbeta inhibitor for PTEN loss. The gene discussed is PTEN; the disease is mismatch repair cancer syndrome 1.